When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MOR - Morphosys up 3% on long-term tafasitamab data in blood cancer
MorphoSys AG
MorphoSys AG (MOR+2.5%) and collaboration partner Incyte (INCY-2.2%) announce two-year follow-up data from a Phase 2 clinical trial, L-MIND, evaluating the combination of tafasitamab and lenalidomide (branded as Revlimid by Celgene) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The results will be presented at the European Hematology Virtual Congress June 11-14.
More news on: MorphoSys AG, Incyte Corporation, Healthcare stocks news, Stocks on the move,